1. A PHASE 1 STUDY OF THE ANTI‐CD37 ANTIBODY‐DRUG CONJUGATE AGS67E IN ADVANCED LYMPHOID MALIGNANCIES. INTERIM RESULTS. (June 2017) Authors: Sawas, A.; Savage, K.J.; Perez, R.P.; Advani, R.H.; Zaine, J.M.; Lackey, J.M.; Trave, F.; Anand, B.; Chu, R.; Reyno, L.M.; O'Connor, O.A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 49 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Analysis of preclinical and clinical samples after treatment with a CD37 targeting antibody drug conjugate (AGS67E) support a high level of CD37 expression in NHL. (June 2017) Authors: Doñate, F.; Yang, P.; Morrison, K.; Karki, S.; Aviña, H.; Lackey, J.M.; Sawas, A.; Savage, K.J.; Perez, R.P.; Advani, R.H.; Zain, J.M.; O'Connor, O.A.; Reyno, L.M. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 290 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗